1. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial. Issue 5 (May 2021) Authors: Risitano, Antonio M; Röth, Alexander; Soret, Juliette; Frieri, Camilla; de Fontbrune, Flore Sicre; Marano, Luana; Alashkar, Ferras; Benajiba, Lina; Marotta, Serena; Rozenberg, Izabela; Milojevic, Julie; End, Peter; Nidamarthy, Prasanna K; Junge, Guido; Peffault de Latour, Régis Journal: Lancet Issue: Volume 8:Issue 5(2021) Page Start: e344 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study. (March 2020) Authors: Fisher, Benjamin A; Szanto, Antonia; Ng, Wan-Fai; Bombardieri, Michele; Posch, Maximilian G; Papas, Athena S; Farag, Arwa M; Daikeler, Thomas; Bannert, Bettina; Kyburz, Diego; Kivitz, Alan J; Carsons, Steven E; Isenberg, David A; Barone, Francesca; Bowman, Simon J; Espié, Pascal; Floch, David; Du... Journal: Lancet Issue: Volume 2:Number 3(2020) Page Start: e142 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. First‐in‐human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti‐CD40 monoclonal antibody. Issue 2 (6th December 2019) Authors: Espié, Pascal; He, YanLing; Koo, Phillip; Sickert, Denise; Dupuy, Cyrielle; Chokoté, Edwige; Schuler, Roland; Mergentaler, Heidi; Ristov, Jacinda; Milojevic, Julie; Verles, Aurelie; Groenewegen, Andrea; Auger, Anita; Avrameas, Alexandre; Rotte, Michael; Colin, Laurence; Tomek, Charles S.; Hernand... Journal: American journal of transplantation Issue: Volume 20:Issue 2(2020) Page Start: 463 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. MO042LNP023: A NOVEL ORAL COMPLEMENT ALTERNATIVE PATHWAY FACTOR B INHIBITOR FOR THE TREATMENT OF GLOMERULAR DISEASE. (6th June 2020) Authors: Webb, Nicholas; Haraldsson, Boerje; Schubart, Anna; Milojevic, Julie; End, Peter; Holbro, Thomas; Junge, Guido Journal: Nephrology dialysis transplantation Issue: Volume 35(2020)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis. Issue 6 (3rd August 2019) Authors: Bruin, Gerard; Hasselberg, Anke; Koroleva, Irina; Milojevic, Julie; Calonder, Claudio; Soon, Rachel; Woessner, Ralph; Pariser, David M.; Boutouyrie‐Dumont, Bruno Journal: Clinical pharmacology & therapeutics Issue: Volume 106:Issue 6(2019) Page Start: 1380 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗